Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Combination of egf/ghrp-6 for neuroregeneration of central nervous system

A GHRP-6, autoimmune technology, applied in the field of compositions containing epidermal growth factor and ghrelin-6, which can solve problems such as lack of combination therapy

Active Publication Date: 2008-05-14
CENT DE ING GENETICA & BIOTECNOLOGIA
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Combination therapy with multiple growth factors or one of them with alternative molecules with positive nutritional effects on the CNS is still lacking

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] The therapeutic effect of embodiment 1.EGF / GHRP-6 drug combination in experimental autoimmune encephalitis (EAE) biological model

[0025] To evaluate the therapeutic efficacy of the EGF / GHRP-6 drug combination, an animal model of EAE, which represents the animal form of the human disease of multiple sclerosis, was established.

[0026] On days 0 and 6, female Lewis rats (130 g) were immunized subcutaneously with guinea pig spinal cord homogenate (5 mg) in PBS (50%) and complete Freund's adjuvant (50%). Ten days after the first immunization, the combined EGF / GHRP-6 (200 μg / kg / day-740 μg / kg / day), the active ingredient EGF alone (200 μg / kg / day), GHRP-6 (740 μg / kg / day) days) and placebo (PBS) to initiate the treatment regimen. The regimen was followed for 10 days using intraperitoneal administration. Clinical scores are based on the following grading: 0; asymptomatic, 1; tail paralysis, 2; any hind limb paralysis, 3; complete hind limb paralysis, 4; complete forelimb and...

Embodiment 2

[0034] The protective effect of EGF / GHRP-6 drug combination in the prevention scheme of embodiment 2.EAE animal model

[0035] To assess the prophylactic effect of the EGF / GHRP-6 combination in an animal model of EAE representing MS human disease, guinea pig spinal cord in PBS (50%) and complete Freund's adjuvant (50%) was used on days 0 and 6 The homogenate (5mg) was subcutaneously immunized into female Lewis rats (130g). Ten days before the first immunization, use EGF / GHRP-6 combination (200μg / kg / day-740μg / kg / day) and active ingredients EGF (200μg / kg / day), GHRP-6 (740μg / kg / day) kg / day) and placebo (PBS) to initiate the prophylaxis regimen. This prophylaxis protocol was followed for 10 days (-10 to -1 days before the first immunization), using the intraperitoneal route of administration. Clinical scores are based on the following grading: 0; asymptomatic, 1; tail paralysis, 2; any hind limb paralysis, 3; complete hind limb paralysis, 4; complete forelimb and hind limb paral...

Embodiment 3

[0043] Example 3. Dosage studies, synergy-enhancement between active ingredients of pharmaceutical combinations

[0044] The therapeutically effective dose range of the pharmaceutical composition was found and the combination was used in the EAE model described above. On days 0 and 6, female Lewis rats (130 g) were immunized subcutaneously with guinea pig spinal cord homogenate (5 mg) in PBS (50%) and complete Freund's adjuvant (50%). The treatment regimen was initiated ten days after the first immunization with different concentrations of EGF / GHRP-6 combinations.

[0045] EGF / GHRP-6 (400μg / kg / day-1480μg / kg / day).

[0046] EGF / GHRP-6 (200μg / kg / day-740μg / kg / day).

[0047] EGF / GHRP-6 (100μg / kg / day-340μg / kg / day)

[0048] EGF / GHRP-6 (50μg / kg / day-170μg / kg / day)

[0049] EGF / GHRP-6 (25μg / kg / day-85μg / kg / day)

[0050] EGF / GHRP-6 (12μg / kg / day-40μg / kg / day)

[0051] The regimen was followed for 10 days using intraperitoneal administration. Clinical scores are based on the following ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention is intended to simulate neuroregeneration of the central nervous system following autoimmune damage. More specifically, the invention relates to the pharmaceutical combination comprising therapeutically-effective concentrations of epidermal growth factor and human growth hormone secretagogue hexapeptide, which is administered to a patient suffering from the symptoms of multiple sclerosis and neuromyelitis optica and which corrects demyelination caused by autoreactive cells in the central nervous system.

Description

field of invention [0001] The present invention relates to medicine, and more particularly to neurology, and to stimulating regeneration of central nervous system nerves after autoimmune injury, in particular by administering a composition comprising epidermal growth factor and ghrelin-6, for the treatment and Prevention of relapse in patients with multiple sclerosis and neuromyelitis optica. Background technique [0002] Multiple sclerosis (MS) and neuromyelitis optica (NO) are autoimmune demyelinating diseases that affect young people, mainly women, producing insufficiency and debilitation that evolve unfavorably over time. MS incidence is strongly correlated with advanced parameters of industrialization and development in first world countries. The central nervous system is a privileged immunological site in which autoimmune responses are rarely found. This occurs when, for undetermined reasons, the cellular and humoral regulatory mechanisms fail, which determine the pe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/18A61K38/08A61K38/25A61P25/28
CPCA61K38/08A61K38/25A61K38/1808A61P25/00A61P25/02A61P25/28A61P27/02A61P37/06A61P43/00A61P5/00A61K2300/00
Inventor D·加西亚德尔巴尔科埃雷拉G·E·纪廉涅托J·A·贝兰加阿科斯塔F·D·L·M·弗雷雷阿尔梅达D·西夫里安贝拉E·彭顿阿里亚斯
Owner CENT DE ING GENETICA & BIOTECNOLOGIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com